KEGG   DISEASE: Esophageal cancer
H00017                      Disease                                
Esophageal cancer
Esophageal cancer represents the 9th leading cancer in the world and is associated with a 5-year survival rate under 25%. The two main forms are squamous-cell carcinoma (ESCC) and adenocarcinoma (EAC). ESCC is the most frequent histological subtype in esophageal cancer, although the incidence of EAC is increasing faster than any other malignancy in the western world. Whereas ESCC can be attributed to alcohol and tobacco consumption, the most important risk factor for the development of EAC is duodenal-gastric-esophageal reflux. In the process of tumorigenesis at the cellular level, multiple genetic alterations are involved, including mutation of the p53 gene, amplification of cyclin D1 gene, among others.
Human diseases in ICD-11 classification [BR:br08403]
 02 Neoplasms
  Malignant neoplasms, except primary neoplasms of lymphoid, haematopoietic, central nervous system or related tissues
   Malignant neoplasms, stated or presumed to be primary, of specified sites, except of lymphoid, haematopoietic, central nervous system or related tissues
    Malignant neoplasms of digestive organs
     2B70  Malignant neoplasms of oesophagus
      H00017  Esophageal cancer
hsa04110  Cell cycle
hsa04218  Cellular senescence
EGFR (overexpression) [HSA:1956] [KO:K04361]
PTGS2 (overexpression) [HSA:5743] [KO:K11987]
NOS2 (increased expression) [HSA:4843] [KO:K13241]
FAS (increased expression) [HSA:355] [KO:K04390]
CCND1 (amplification) [HSA:595] [KO:K04503]
TP53 [HSA:7157] [KO:K04451]
CDKN2A [HSA:1029] [KO:K06621]
RB1 [HSA:5925] [KO:K06618]
APC [HSA:324] [KO:K02085]
DCC [HSA:1630] [KO:K06765]
LZTS1 [HSA:11178] [KO:K26460]
RNF6 [HSA:6049] [KO:K22753]
TGFBR2 [HSA:7048] [KO:K04388]
WWOX [HSA:51741] [KO:K19329]
Capecitabine [DR:D01223]
Floxuridine [DR:D04197]
Nivolumab [DR:D10316]
Pembrolizumab [DR:D10574] (PD-L1 expressed)
Porfimer sodium [DR:D03327]
Other DBs
ICD-11: 2B70
ICD-10: C15
MeSH: D004938
OMIM: 133239
PMID:15622457 (EGFR, TP53, PTGS2, NOS2, CCND1, CDKN2A, RB1)
Kuwano H, Kato H, Miyazaki T, Fukuchi M, Masuda N, Nakajima M, Fukai Y, Sohda M, Kimura H, Faried A.
Genetic alterations in esophageal cancer.
Surg Today 35:7-18 (2005)
PMID:12951586 (APC, CDKN2A, NOS2, RB1, PTGS2, TP53, RB1, EGFR, FAS)
Wild CP, Hardie LJ.
Reflux, Barrett's oesophagus and adenocarcinoma: burning questions.
Nat Rev Cancer 3:676-84 (2003)
PMID:15914317 (CCND1, TP53, RB1, CDKN2A, APC, WWOX, FAS)
McCabe ML, Dlamini Z.
The molecular mechanisms of oesophageal cancer.
Int Immunopharmacol 5:1113-30 (2005)
PMID:8187090 (DCC)
Miyake S, Nagai K, Yoshino K, Oto M, Endo M, Yuasa Y
Point mutations and allelic deletion of tumor suppressor gene DCC in human esophageal squamous cell carcinomas and their relation to metastasis.
Cancer Res 54:3007-10 (1994)
PMID:11504921 (LZTS1)
Ishii H, Vecchione A, Murakumo Y, Baldassarre G, Numata S, Trapasso F, Alder H, Baffa R, Croce CM
FEZ1/LZTS1 gene at 8p22 suppresses cancer cell growth and regulates mitosis.
Proc Natl Acad Sci U S A 98:10374-9 (2001)
PMID:12154016 (RNF6)
Lo HS, Hu N, Gere S, Lu N, Su H, Goldstein AM, Taylor PR, Lee MP
Identification of somatic mutations of the RNF6 gene in human esophageal squamous cell carcinoma.
Cancer Res 62:4191-3 (2002)
PMID:10789724 (TGFBR2)
Tanaka S, Mori M, Mafune K, Ohno S, Sugimachi K
A dominant negative mutation of transforming growth factor-beta receptor type II gene in microsatellite stable oesophageal carcinoma.
Br J Cancer 82:1557-60 (2000)
PMID:11956080 (WWOX)
Kuroki T, Trapasso F, Shiraishi T, Alder H, Mimori K, Mori M, Croce CM
Genetic alterations of the tumor suppressor gene WWOX in esophageal squamous cell carcinoma.
Cancer Res 62:2258-60 (2002)

» Japanese version

DBGET integrated database retrieval system